ArticleBiotechnology letters2026
High-level secretory production of a highly hydrophilic human-like type III collagen in Komagataella phaffii by a multicopy genomic integration strategy.
Article in Biotechnology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Collagen, a key extracellular matrix protein, regulates cell adhesion, proliferation, and tissue integrity for skin health. In this study, a novel human-like type III collagen was engineered by substituting hydrophobic GXY triplets in the core fragment (Gly201-Asn498) of the human α1(III)type chain with hydrophilic motifs (GSP, GQP, GEP, and GSQ) and incorporating integrin-binding sequences (GER and RGD) at the C-terminus of the two consecutive sequence units. The codon-optimized gene was cloned into the pPIC9K vector, and transformed into Komagataella phaffii (Pichia pastoris) GS115. Multicopy transformants were selected by various G418 concentrations. Furthermore, a high yield of recombinant collagen at 19.4 g/L was achieved by fed-batch fermentation in a 5-L bioreactor. The purified protein exhibited excellent thermostability, remaining fully soluble after heating at 121 °C for 30 min. The collagen migrated on 10% SDS-PAGE with an apparent molecular weight approximately 2.18-fold greater than its theoretical mass, suggesting extensive hydration. Functionally, it significantly promoted the proliferation of human skin fibroblasts (HSF) and immortalized keratinocytes (HaCaT). In HSF cells, it upregulated the expression of COL1A1, COL3A1, and TIMP1, while in HaCaT cells, it enhanced transcription of skin barrier-related genes, including KRT1, KRT5, KRT10, KRT14, IVL, LOR, and FLG. This designed collagen integrates high-yield production, thermostability, and dual bioactivity for dermal regeneration and epidermal barrier reinforcement, showing a promising application for skincare and tissue engineering.
Indexed as
Identifiers
42217068What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.